查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010046

疫苗市场：2026-2032年全球市场预测（按类型、疫苗配方、疾病、疫苗分类、给药途径、剂量、年龄层和最终用户划分）

Vaccines Market by Type, Vaccine Combination, Disease Indication, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疫苗市值将达到 902.1 亿美元，到 2026 年将成长至 971.4 亿美元，到 2032 年将达到 1523.1 亿美元，复合年增长率为 7.76%。

主要市场统计数据
基准年 2025 902.1亿美元
预计年份：2026年 971.4亿美元
预测年份 2032 1523.1亿美元
复合年增长率 (%) 7.76%

我们将透过前所未有的科学突破和全球公共卫生合作，开启疫苗创新的新时代。

疫苗已成为现代医学最重要的成就之一，它透过每年预防数百万人死亡和减轻全球疾病负担，大大改善了公共卫生状况。近年来，一系列卓越的科学突破加速了疫苗研发进程，使我们能够以前所未有的方式应对新兴感染疾病的威胁。本节将介绍疫苗研究的背景，重点关注快速的技术进步、监管模式转移以及不断变化的全球需求。

即时识别疫苗研发和分发中正在重新定义全球医疗保健的根本性变革。

在科学创新与全球健康需求的共同推动下，疫苗产业经历了根本性的变革。而这场改变的核心在于传讯RNA（mRNA）技术的快速成熟。这项技术已展现出以前所未有的速度和精准度研发标靶疫苗的能力。因此，许多研发人员正大力投资于基于平台的疫苗研发方法，以实现针对不同病原体的模组化免疫回应。

评估美国2025年新关税措施对疫苗供应、供应链和产业趋势的影响。

2025年，美国实施的新关税给全球疫苗供应链带来了巨大压力。对关键原料和成品疫苗成分征收的进口关税增加了依赖跨境采购的製造商的生产成本。这些成本压力促使许多公司探索国内生产方案，加速了对区域生物技术丛集和合约研发生产机构（CDMO）的投资。

阐明疫苗市场区隔（类型、产品类型、分类、给药方法、剂量、年龄组等）的全面见解。

对疫苗平台的检验揭示了该领域的多样性。虽然灭活疫苗仍然是许多国家免疫规划的基础，但减毒活病毒疫苗持续为人们提供针对麻疹、腮腺炎和德国德国麻疹（MMR）以及日本脑炎等疾病的持久免疫力。同时，传讯RNA（mRNA）疫苗的迅速崛起带来了模式转移，利用核酸递送系统来靶向更广泛的病原体。

本分析检视了美洲、欧洲、中东和非洲以及亚太地区疫苗市场的区域差异，重点介绍了独特的机会和挑战。

在北美生物技术中心的大量投资推动下，美洲在疫苗研发和商业化方面继续发挥核心作用。美国和加拿大的监管机构已采取先进的框架来加快核准，从而培育出一个有利于创新的生态系统。拉丁美洲国家正在推动区域生产合作，以减少对进口的依赖，并透过公共卫生倡议提高免疫接种率。

透过策略联盟、产品平臺和投资重点，分析推动疫苗创新和市场扩张的主要企业。

领先的生物技术和製药公司正在加强合作，以提高研发和生产效率。成熟疫苗生产商与专业生物技术公司之间的策略伙伴关係正在加速下一代平台的开发。这些伙伴关係通常将深厚的免疫学专业知识与先进的递送技术相结合，以加速新型抗原的临床开发。

为产业领导者应对不断变化的疫苗格局提出的策略建议：加强供应链和加快研发进程。

为了保持竞争优势，产业领导者应整合能够灵活切换平台和剂型的生产模式，并实现製造地多元化。采用模组化设施和一次性技术，能够在公共卫生紧急情况下快速扩大生产规模，从而在不影响营运灵活性的前提下，支援更广泛的产品系列。

疫苗市场分析中使用的调查方法详情，包括资料收集、检验、三角测量和专家访谈。

本研究整合了第一手和第二手调查方法调查方法，以确保全面覆盖和深入洞察。第一手资料透过访谈顶尖免疫学家、製造专家和政策制定者收集，从而获得关于技术趋势、监管变化和市场驱动因素的第一手观点。这些定性资讯辅以基于同行评审期刊、行业出版物和公共卫生组织报告的第二手研究，以检验新出现主题的相关性。

总结疫苗市场动态趋势的关键发现和策略意义，以支持相关人员在复杂的公共卫生挑战时代做出决策。

分析表明，传讯RNA（mRNA）和病毒载体等技术创新正在重新定义疫苗研发的模式。这些进步与不断完善的监管流程和公私合营相辅相成，加速了临床开发并增强了生产韧性。所有这些因素共同促成了对新出现的健康威胁做出更积极主动的应对。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：疫苗市场：按类型划分

  • 灭活疫苗
  • 减毒活病毒疫苗
  • 传讯RNA疫苗
  • 次单元、重组疫苗、多醣体疫苗和结合疫苗
  • 类毒素疫苗
  • 病毒载体疫苗

第九章：以疫苗组合分類的疫苗市场

  • 单价疫苗
  • 多价疫苗

第十章：疫苗市场：依疾病适应症划分

  • 感染疾病疫苗
    • 流感
    • 甲型和乙型肝炎
    • 脊髓灰质炎
    • COVID-19
    • 肺炎链球菌和脑膜炎球菌病菌感染
    • 人类乳突病毒（HPV）
    • 轮状病毒
    • 登革热
    • 疟疾
    • 狂犬病
  • 非感染疾病疫苗
    • 癌症疫苗
    • 过敏疫苗
    • 阿兹海默症疫苗

第十一章：疫苗市场：依疫苗分类

  • 预防性疫苗
  • 治疗性疫苗

第十二章：疫苗市场：依给药途径划分

  • 肌肉内部
  • 鼻内
  • 口服
  • 皮下

第十三章：疫苗市场：依剂量划分

  • 多次给药
  • 单一剂量

第十四章：疫苗市场：依年龄组别划分

  • 成人版
  • 老年人
  • 儿童
    • 婴儿
    • 婴儿

第十五章：疫苗市场：依最终用户划分

  • 学术和研究机构
  • 医院和诊所
  • 疫苗接种中心

第十六章：疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国疫苗市场

第二十章：中国疫苗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Pfizer Inc.
  • BioNTech SE
  • Sinovac Biotech Ltd.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • AstraZeneca PLC
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 90.21 billion in 2025 and is projected to grow to USD 97.14 billion in 2026, with a CAGR of 7.76%, reaching USD 152.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 90.21 billion
Estimated Year [2026] USD 97.14 billion
Forecast Year [2032] USD 152.31 billion
CAGR (%) 7.76%

Pioneering the Next Era of Vaccine Innovation Through Unprecedented Scientific Breakthroughs and Global Collaboration in Public Health

Vaccines have emerged as one of the most significant triumphs in modern medicine, transforming public health by preventing millions of deaths annually and reducing disease burden across the globe. Recent years have witnessed extraordinary scientific breakthroughs that have accelerated vaccine development timelines, enabling unprecedented responses to emerging infectious threats. This section introduces the context of vaccine research in a landscape defined by rapid technological advances, shifting regulatory paradigms, and evolving global needs.

The integration of cutting-edge platforms such as messenger RNA and viral vectors has redefined the possibilities for preventive and even therapeutic immunizations. These innovations are complemented by advancements in adjuvant technology, antigen design, and delivery systems that optimize immune responses while minimizing adverse events. As a result, vaccine developers are exploring novel targets ranging from infectious diseases to oncology and chronic conditions, signaling a broader scope of applications than ever before.

Beyond the laboratory, collaboration between academic institutions, biotechnology firms, and governmental agencies has intensified. Public-private partnerships have streamlined clinical trial processes and bolstered manufacturing capacity, ensuring that supply chains remain resilient in the face of disruptions. Simultaneously, digital tools for data collection, analysis, and post-market safety monitoring are enhancing transparency and building public trust. This introduction sets the stage for an in-depth exploration of transformative shifts, regional dynamics, and strategic imperatives shaping the future of vaccines.

Identifying Fundamental Transformations in Vaccine Development and Distribution That Are Redefining Preventive Healthcare Worldwide in Real Time

The vaccine industry has undergone fundamental transformations driven by the convergence of scientific innovation and global health imperatives. At the forefront is the rapid maturation of messenger RNA technology, which has demonstrated the capacity to create targeted immunizations with unprecedented speed and precision. This has prompted many developers to invest heavily in platform-based approaches, enabling modular responses to a diversity of pathogens.

Equally transformative is the rise of flexible manufacturing paradigms. The adoption of modular bioprocessing units and single-use technologies has decentralized production, allowing facilities to pivot quickly in response to surges in demand. Concurrently, advanced cold chain solutions and real-time monitoring systems have mitigated logistical challenges, ensuring that vaccines maintain potency from site to site and reach communities in remote regions.

Regulatory landscapes have adapted accordingly, introducing accelerated pathways such as rolling reviews and conditional approvals to expedite access during public health emergencies. At the same time, emphasis on equity has grown, with global initiatives promoting tiered pricing, technology transfer agreements, and local manufacturing partnerships. These shifts reflect a broader transformation in which preventive healthcare is being reimagined as an integrated endeavor that extends from discovery science through distribution, laying the foundation for more agile and inclusive immunization strategies.

Public perception and demand are also shifting alongside these developments. Enhanced transparency in clinical data sharing, coupled with targeted education campaigns, is improving vaccine literacy and acceptance. This cultural evolution underscores the importance of aligning scientific progress with community engagement, ultimately reinforcing the resilience of immunization programs against emerging challenges, from novel pathogens to vaccine hesitancy.

Evaluating the Consequences of New Tariff Measures in the United States on Vaccine Accessibility Supply Chains and Industry Dynamics in 2025

In 2025, the imposition of new tariff measures by the United States has exerted significant pressure on global vaccine supply chains. Import duties applied to critical raw materials and finished vaccine components have increased production costs for manufacturers that rely on cross-border procurement. These cost pressures have prompted many firms to explore domestic manufacturing options, accelerating investments in local biotechnology clusters and contract development and manufacturing organizations.

The ripple effects extend beyond cost management. Suppliers in Asia-Pacific and Europe have reexamined their export strategies in response to changing trade equations, seeking alternative markets or negotiating revised supply agreements. At the same time, vaccine developers are reassessing pricing strategies and contractual terms to ensure continuity of supply for public health programs and private sector clients. This recalibration is reshaping procurement practices and influencing long-term strategic partnerships.

Policymakers have been compelled to navigate a delicate balance between safeguarding domestic industries and preserving access to essential immunizations. Collaborative dialogues between government agencies, industry associations, and international bodies have been vital in mitigating the risk of shortages. These engagements have helped establish exceptions for critical health commodities, underscoring the recognition of vaccines as strategic assets in national security and public welfare.

As a result, the vaccine ecosystem is evolving toward a hybrid model that blends localized production resilience with global distribution efficiencies. Although the immediate impact of trade measures has introduced complexity, the longer-term effect may be a more robust and diversified supply network capable of responding to emergent health threats with greater agility.

Unraveling Comprehensive Insights Across Vaccine Market Segmentation Including Type Product Combination Classification Administration Dosage and Age Group

The sector's heterogeneity becomes evident when examining vaccine platforms. Inactivated formulations remain a cornerstone in many national immunization programs, while live-attenuated vaccines continue to provide durable immunity against diseases such as measles-mumps-rubella and Japanese encephalitis. At the same time, the rapid ascendance of messenger RNA vaccines has introduced a paradigm shift, leveraging nucleic acid-based delivery systems to target a wider range of pathogens.

Within product segments, the COVID-19 vaccine category has catalyzed unprecedented attention to development speed and distribution networks, influencing the strategies for hepatitis and influenza immunizations. Vaccines designed for rotavirus and human papillomavirus underscore the expanding focus on preventive measures against chronic and oncogenic conditions. Mono-valent doses offer targeted protection, whereas multi-valent formulations deliver broader coverage, reducing the number of administrations required for comprehensive immunization schedules.

Classification-based insights reveal that preventive vaccines dominate market priorities, yet therapeutic vaccines targeting oncology and chronic diseases are gaining traction. Routes of administration further differentiate offerings, with intramuscular injections remaining prevalent and emerging interest in intranasal and oral delivery systems driven by ease of administration, patient compliance, and cold chain considerations. Multi-dose vials support mass immunization campaigns, while single-dose formats align with on-demand and travel medicine requirements.

Age group segmentation highlights distinctive requirements, with pediatric vaccines tailored to infants and toddlers under rigorous safety standards, whereas adult and geriatric programs emphasize booster schedules and combined formulations. Finally, end-user categories span academic and research institutes that pioneer initial development to hospitals, clinics, and dedicated vaccination centers that administer immunizations at scale. Together, these segmentation layers paint a nuanced portrait of the vaccine landscape, informing targeted strategies for product development and market entry.

Analyzing Regional Vaccine Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Highlight Unique Opportunities and Challenges

The Americas continue to play a central role in vaccine research and commercialization, driven by substantial investment in biotech hubs across North America. Regulatory authorities in the United States and Canada have adopted progressive frameworks that facilitate expedited approvals, fostering an ecosystem conducive to innovation. Latin American nations have pursued regional manufacturing collaborations to reduce reliance on imports and enhance immunization coverage through public health initiatives.

Europe, Middle East, and Africa represent a mosaic of established markets and emerging economies. The European Union benefits from harmonized regulatory standards and robust manufacturing capacity, while nations across the Middle East are investing in domestic capabilities to address regional health priorities. Sub-Saharan Africa has seen renewed emphasis on vaccine equity, with international partnerships supporting cold chain infrastructure and local clinical trial networks aimed at combating endemic diseases.

In Asia-Pacific, dynamic growth is underpinned by a diverse array of stakeholders. Industrial powerhouses leverage advanced bioprocessing technologies to produce a significant share of global vaccine volumes, while emerging markets such as Southeast Asia increase immunization rates through government-driven programs. Collaboration between multinational corporations and local manufacturers is expanding capacity and tailoring vaccine portfolios to regional epidemiological needs. Collectively, this regional tapestry underscores the importance of context-specific approaches to optimize vaccine delivery and policy frameworks worldwide.

Profiling Leading Companies Driving Vaccine Innovation and Market Expansion Through Strategic Collaborations Product Pipelines and Investment Priorities

Major biotechnology and pharmaceutical companies have intensified collaboration efforts to enhance research and manufacturing efficiency. Strategic alliances between established vaccine producers and specialized biotechnology firms are fostering the development of next-generation platforms. These partnerships often combine deep immunology expertise with advanced delivery technologies, accelerating the translation of novel antigens into clinical candidates.

Companies with expansive product pipelines are diversifying their portfolios beyond traditional indications. While a handful of global leaders maintain broad franchises across influenza, hepatitis, and pediatric immunizations, emerging players are focusing on niche segments, including therapeutic vaccines for oncology and chronic infections. Investments in process development, high-throughput screening, and artificial intelligence-driven antigen design are positioning these firms to capture growth in both preventive and therapeutic domains.

On the manufacturing front, industry leaders are scaling up capacity through greenfield plants and capacity expansions in strategic locations. Advanced facilities equipped with continuous bioprocessing and digital quality management systems are becoming the norm, reducing time to market and ensuring regulatory compliance. At the same time, companies are forging collaborations with contract manufacturing organizations to gain flexibility and mitigate supply chain risk.

Financial commitment to research and development remains robust, with capital allocated toward platform innovation, adjuvant discovery, and novel delivery systems. This investment landscape is supported by venture capital activity and public funding initiatives aimed at building resilient vaccine ecosystems. Collectively, these corporate strategies illuminate the competitive dynamics and growth drivers shaping the future of the vaccine industry.

Recommending Strategic Actions for Industry Leaders to Navigate Evolving Vaccine Landscapes Enhance Supply Chains and Accelerate Development Pathways

To maintain a competitive edge, industry leaders should diversify manufacturing footprints by integrating flexible production models that can pivot between platforms and dosage forms. Embracing modular facilities and single-use technologies will enable rapid scale-up during public health emergencies and support a broader product portfolio without compromising operational agility.

Strengthening the upstream supply chain is equally critical. Establishing partnerships with raw material suppliers in key regions can buffer against trade disruptions and tariff implications. Long-term procurement agreements coupled with transparent forecasting practices will enhance supplier relationships and reduce lead times, ensuring consistent material availability for complex biologic processes.

Investment in digital end-to-end visibility solutions can optimize cold chain integrity and distribution efficiency. Real-time data analytics and blockchain-enabled tracking systems will improve traceability and compliance, reducing wastage and supporting regulatory reporting requirements. Furthermore, integrating digital platforms for patient engagement and adherence monitoring can enhance immunization coverage and post-market surveillance.

Collaborations between industry, academia, and government agencies should be reinforced to accelerate innovation pipelines. Joint research consortia and public funding mechanisms can de-risk early-stage development and foster knowledge exchange. Finally, proactive engagement with regulatory bodies to shape policies on accelerated approvals and standardized data requirements will facilitate smoother market entry and timely access to life-saving vaccines.

Detailing Research Methodology Employed in Vaccine Market Analysis Including Data Collection Validation Triangulation and Expert Consultations

The research framework integrates both primary and secondary methodologies to ensure comprehensive coverage and robust insights. Primary data was gathered through interviews with leading immunologists, manufacturing experts, and policy makers, providing first-hand perspectives on technological trends, regulatory shifts, and market drivers. These qualitative inputs were augmented by secondary research drawing on peer-reviewed journals, industry publications, and official health agency reports to validate emerging themes.

Data validation and triangulation processes were employed to cross-verify information from disparate sources. Quantitative data points were examined for consistency across multiple publications, while qualitative insights were compared against real-world case studies and clinical trial outcomes. This multi-dimensional approach enabled the identification of convergent patterns and the resolution of any anomalies.

Analytical frameworks such as SWOT analysis, PESTEL evaluation, and Porter's Five Forces were applied to structure the findings and uncover strategic implications. Regional segmentation and supply chain mapping exercises further contextualized the data, highlighting critical inflection points and potential bottlenecks. Attention to methodological transparency and reproducibility was maintained throughout the research lifecycle.

Continuous quality control measures were instituted, including peer reviews by external experts and rigorous editorial oversight, ensuring that insights are both reliable and actionable. This methodology provides a solid foundation for understanding the complexities of the vaccine market, guiding stakeholders through an evolving landscape shaped by innovation and policy dynamics.

Summarizing Key Findings and Strategic Implications of Vaccine Market Dynamics to Inform Stakeholder Decisions in an Era of Complex Public Health Challenges

The analysis reveals that technological innovations, notably messenger RNA and viral vector platforms, are redefining the vaccine development paradigm. These advances are complemented by progressive regulatory pathways and public-private collaborations that expedite clinical progression and bolster manufacturing resilience. Together, these elements are enabling a more proactive response to emergent health threats.

Trade policies and regional dynamics exert profound influence on supply chain configurations, necessitating strategic approaches to mitigate cost pressures while maintaining global access. The evolving segmentation landscape, encompassing diverse vaccine types, administration routes, and dosage formats, underscores the importance of tailored strategies that address distinct demographic and epidemiological requirements.

Leading companies are capitalizing on robust pipelines and strategic alliances to drive market expansion, while investment in advanced manufacturing and digital platforms enhances operational efficiency. Regional disparities between the Americas, Europe Middle East & Africa, and Asia-Pacific highlight the need for contextualized solutions to optimize distribution and policy frameworks.

Strategic imperatives for stakeholders include diversifying production capabilities, fortifying supply chain partnerships, and leveraging digital tools for end-to-end visibility. Collaborative research models and early engagement with regulatory bodies will further accelerate innovation trajectories. These insights provide a roadmap for decision-makers seeking to navigate a landscape defined by rapid change and high stakes in global public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccines Market, by Type

  • 8.1. Inactivated Vaccines
  • 8.2. Live-Attenuated Vaccines
  • 8.3. Messenger RNA Vaccines
  • 8.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 8.5. Toxoid Vaccines
  • 8.6. Viral Vector Vaccines

9. Vaccines Market, by Vaccine Combination

  • 9.1. Mono-Valent Vaccines
  • 9.2. Multi-Valent Vaccines

10. Vaccines Market, by Disease Indication

  • 10.1. Infectious Disease Vaccines
    • 10.1.1. Influenza
    • 10.1.2. Hepatitis A & B
    • 10.1.3. Polio
    • 10.1.4. COVID-19
    • 10.1.5. Pneumococcal & Meningococcal Disease
    • 10.1.6. Human Papillomavirus HPV
    • 10.1.7. Rotavirus
    • 10.1.8. Dengue
    • 10.1.9. Malaria
    • 10.1.10. Rabies
  • 10.2. Non-Infectious Disease Vaccines
    • 10.2.1. Cancer Vaccines
    • 10.2.2. Allergy Vaccines
    • 10.2.3. Alzheimer's Vaccines

11. Vaccines Market, by Vaccine Classification

  • 11.1. Preventive Vaccines
  • 11.2. Therapeutic Vaccines

12. Vaccines Market, by Route of Administration

  • 12.1. Intramuscular
  • 12.2. Intranasal
  • 12.3. Oral
  • 12.4. Subcutaneous

13. Vaccines Market, by Dosage

  • 13.1. Multi Dose
  • 13.2. Single Dose

14. Vaccines Market, by Age Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric
    • 14.3.1. Infants
    • 14.3.2. Toddlers

15. Vaccines Market, by End User

  • 15.1. Academic & Research Institutes
  • 15.2. Hospitals & Clinics
  • 15.3. Vaccination Centers

16. Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Vaccines Market

20. China Vaccines Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Pfizer Inc.
  • 21.6. BioNTech SE
  • 21.7. Sinovac Biotech Ltd.
  • 21.8. Moderna, Inc.
  • 21.9. Merck & Co., Inc.
  • 21.10. GlaxoSmithKline PLC
  • 21.11. Sanofi S.A.
  • 21.12. Johnson & Johnson Services, Inc.
  • 21.13. AstraZeneca PLC
  • 21.14. Abbott Laboratories
  • 21.15. Astellas Pharma Inc.
  • 21.16. Bavarian Nordic A/S
  • 21.17. Bharat Biotech Ltd.
  • 21.18. Biological E. Limited
  • 21.19. Blue Lake Biotechnology
  • 21.20. Capricor Therapeutics, Inc.
  • 21.21. Chongqing Zhifei Biological Products Co., Ltd.
  • 21.22. CSL Limited
  • 21.23. CureVac N.V.
  • 21.24. Daiichi Sankyo Company, Limited.
  • 21.25. Gennova Biopharmaceuticals Limited
  • 21.26. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 21.27. Incepta Pharmaceuticals Ltd.
  • 21.28. Inovio Pharmaceuticals, Inc.
  • 21.29. Novavax, Inc.
  • 21.30. Serum Institute of India Pvt. Ltd.
  • 21.31. Takeda Pharmaceutical Company Limited
  • 21.32. VBI Vaccines Inc.
  • 21.33. Versatope Therapeutics
  • 21.34. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINES MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINES MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINES MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL & MENINGOCOCCAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL & MENINGOCOCCAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL & MENINGOCOCCAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS HPV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS HPV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS HPV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINES MARKET SIZE, BY DENGUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINES MARKET SIZE, BY DENGUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINES MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINES MARKET SIZE, BY MALARIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINES MARKET SIZE, BY MALARIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINES MARKET SIZE, BY MALARIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINES MARKET SIZE, BY ALLERGY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINES MARKET SIZE, BY ALLERGY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINES MARKET SIZE, BY ALLERGY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINES MARKET SIZE, BY ALZHEIMER'S VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINES MARKET SIZE, BY ALZHEIMER'S VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINES MARKET SIZE, BY ALZHEIMER'S VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. GCC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 251. GCC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. G7 VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. NATO VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 291. NATO VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. NATO VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. NATO VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 297. NATO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. NATO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 299. NATO VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA VACCINES MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)